| Abstract |
【Abstracts】ObjectiveTo compare Escitalopram and Paroxetine on the clinical efficacy of patients with post-schizophrenic depression. Methods 80 cases of patients with post-schizophrenic depression, who were recruited from October 2013 to October 2015 in our hospital, were randomly divided into 2 groups: They were maintained the original antipsychotic drug treatment, on this basis, the observation group was applied escitalopram; The control group was treated with paroxetine. They were given continuous medication for 8 weeks, and at 0 week , 1 week, 2 weeks, 4 weeks, 8 weeks of using medicine, efficacy was evaluated by Brief Psychiatric Rating Scale (BPRS) and Hamilton Depression Rating Scale (HAMD) and adverse reaction was evaluated by adverse reaction scale (TESS). Results All patients during the medication period HAMD, BPRS score showed a downward trend, and there was a significant difference (P < 0.05) compared with 0 week of administration; Difference had significant significance （P＜0.05）； There were no significant differences in BPRS score for two groups at each time （P＞0.5）；HAMD score of the observation group after 1 week of administration was significantly lower than that of the control group, there was significant difference between the groups (P < 0.05),and there was no significant difference between groups at other time （P＞0.5）；There was a small amount of adverse reaction between 2 groups , the total incidence of adverse reaction had no significant difference (P > 0.05). The incidence of sexual dysfunction of the observation group was significantly lower than that of the control group (P < 0.05).Conclusion Ai Sciplan and Pa Rossi Dean are reliable drugs for the treatment of depression disorder after schizophrenia, but Ai Sciplan works faster, the impact on sexual function is lighter, it has more universal significance.
|